肺部铜绿假单胞菌感染的抗菌药物治疗研究现状  

Research Status of Antimicrobial Drugs for Pulmonary Pseudomonas Aeruginosa Infection

作　　者：李华燕 晏媛[1] 曾洁[2] 戴涛[1] 赵银萍 LI Huayan;YAN Yuan;ZENG Jie;DAI Tao;ZHAO Yinping(Department of Pharmacy,Zengcheng Branch,Nanfang Hospital,Southern Medical University,Guangzhou 511330,China;Department of Pharmacy,the Fifth Affiliated Hospital of Guangzhou Medical University,Guangzhou 510700,China)

机构地区：[1]南方医科大学南方医院增城分院药学部,广州511330 [2]广州医科大学附属第五医院药学部,广州510700

出　　处：《医学综述》2023年第17期3465-3469,共5页Medical Recapitulate

摘　　要：铜绿假单胞菌(PA)是一种常见的条件致病菌,具有定植能力强、多耐药性等特点,目前临床治疗PA感染以抗菌药物为主。但随着抗菌药物的广泛使用及气管插管、气管切开等有创检查的增加,PA对抗菌药物的耐药性逐渐增强,且可同时对多种抗菌药物耐药,多重耐药的发生导致抗菌药物治疗效果欠佳。肺部是PA感染的频发部位,但PA感染引起的肺部疾病往往治疗难度较大,增加了医疗费用,也是导致患者病死的重要原因,因此肺部PA感染患者抗菌药物的选择仍是目前临床研究热点。Pseudomonas aeruginosa(PA)is a common conditional pathogen,which is characterized by strong colonization ability and multi-drug resistance.At present,the clinical treatment of PA infection is mainly based on antibiotics.However,with the widespread use of antimicrobial drugs and the increase of invasive examinations such as tracheal intubation and tracheotomy,PA′s resistance to antimicrobial drugs has gradually increased,and it can also be resistant to multiple antimicrobial drugs at the same time,leading to the poor effect of antibiotic treatment.The lung is the frequent site of PA infection,and the pulmonary diseases caused by PA infection are often difficult to treat,which not only increases the medical expenses,but also is an important reason for the death of the patients.Therefore,the choice of antimicrobial drugs in patients with pulmonary PA infection is still the focus of clinical research.

关 键 词：肺部疾病 铜绿假单胞菌 耐药性 抗菌药物 

分 类 号：R378[医药卫生—病原生物学] R978.1[医药卫生—基础医学]